{"pre_text": ["hologic , inc .", "notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) fiscal 2007 acquisition : acquisition of biolucent , inc .", "on september 18 , 2007 the company completed the acquisition of biolucent , inc .", "( 201cbiolucent 201d ) pursuant to a definitive agreement dated june 20 , 2007 .", "the results of operations for biolucent have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its mammography/breast care business segment .", "the company has concluded that the acquisition of biolucent does not represent a material business combination and therefore no pro forma financial information has been provided herein .", "biolucent , previously located in aliso viejo , california , develops , markets and sells mammopad breast cushions to decrease the discomfort associated with mammography .", "prior to the acquisition , biolucent 2019s primary research and development efforts were directed at its brachytherapy business which was focused on breast cancer therapy .", "prior to the acquisition , biolucent spun-off its brachytherapy technology and business to the holders of biolucent 2019s outstanding shares of capital stock .", "as a result , the company only acquired biolucent 2019s mammopad cushion business and related assets .", "the company invested $ 1000 directly in the spun-off brachytherapy business in exchange for shares of preferred stock issued by the new business .", "the aggregate purchase price for biolucent was approximately $ 73200 , consisting of approximately $ 6800 in cash and 2314 shares of hologic common stock valued at approximately $ 63200 , debt assumed and paid off of approximately $ 1600 and approximately $ 1600 for acquisition related fees and expenses .", "the company determined the fair value of the shares issued in connection with the acquisition in accordance with eitf issue no .", "99-12 , determination of the measurement date for the market price of acquirer securities issued in a purchase business combination .", "the acquisition also provides for up to two annual earn-out payments not to exceed $ 15000 in the aggregate based on biolucent 2019s achievement of certain revenue targets .", "the company has considered the provision of eitf issue no .", "95-8 , accounting for contingent consideration paid to the shareholders of an acquired enterprise in a purchase business combination , and concluded that this contingent consideration will represent additional purchase price .", "as a result , goodwill will be increased by the amount of the additional consideration , if any , when it becomes due and payable .", "as of september 27 , 2008 , the company has not recorded any amounts for these potential earn-outs .", "the allocation of the purchase price is based upon estimates of the fair value of assets acquired and liabilities assumed as of september 18 , 2007 .", "the components and allocation of the purchase price consists of the following approximate amounts: ."], "post_text": ["as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued .", "it was determined that only customer relationship , trade name and developed technology and know-how had separately identifiable values .", "the fair value of these intangible assets was determined through the application of the income approach .", "customer relationship represents a large customer base that is expected to purchase the disposable mammopad product on a regular basis .", "trade name represents the ."], "table": [["net tangible assets acquired as of september 18 2007", "$ 2800"], ["developed technology and know how", "12300"], ["customer relationship", "17000"], ["trade name", "2800"], ["deferred income tax liabilities net", "-9500 ( 9500 )"], ["goodwill", "47800"], ["final purchase price", "$ 73200"]], "table_ori": [["Net tangible assets acquired as of September 18, 2007", "$2,800"], ["Developed technology and know how", "12,300"], ["Customer relationship", "17,000"], ["Trade name", "2,800"], ["Deferred income tax liabilities, net", "(9,500)"], ["Goodwill", "47,800"], ["Final purchase price", "$73,200"]]}

Question: what is the estimated price of hologic common stock used in the transaction for biolucent acquisition?
Evidence:
text_11: the aggregate purchase price for biolucent was approximately $ 73200 , consisting of approximately $ 6800 in cash and 2314 shares of hologic common stock valued at approximately $ 63200 , debt assumed and paid off of approximately $ 1600 and approximately $ 1600 for acquisition related fees and expenses .
Program: divide(63200, 2314)
Answer:
str_answer: 27.3
exe_answer: 27.31201